|
Nasal Polyps
|
0.410 |
GeneticVariation
|
disease |
BEFREE |
Most notably, a missense variant in ALOX15 that causes a p.Thr560Met alteration in arachidonate 15-lipoxygenase (15-LO) confers large genome-wide significant protection against NP (P = 8.0 × 10<sup>-27</sup>, odds ratio = 0.32; 95% confidence interval = 0.26, 0.39) and CRS (P = 1.1 × 10<sup>-8</sup>, odds ratio = 0.64; 95% confidence interval = 0.55, 0.75). p.Thr560Met, carried by around 1 in 20 Europeans, was previously shown to cause near total loss of 15-LO enzymatic activity.
|
30643255 |
2019 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
12/15-LOXs are capable of oxidizing lipoproteins (low-density lipoprotein (LDL), high-density lipoprotein (HDL)) to atherogenic forms, and functional inactivation of this enzyme in murine atherosclerosis models slows down lesion formation.
|
16270276 |
2005 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Also, overexpression of the 15-LOX Type 1 in transgenic rabbits leads to a reduced inflammatory phenotype and protection from periodontal disease, as well as atherosclerosis.
|
15584868 |
2004 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, the paradoxical increase in LDL oxidation by endothelial cells is attributable to higher oxidant activity of 12/15-lipoxygenase in BALB/c mice and endothelial cells appear unlikely to be a source of the resistance to atherosclerosis.
|
16919636 |
2007 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that ALOX15 may play a less prominent role during later stages of atherosclerosis involving atherothrombotic mechanisms than eventually during early plaque development.
|
19131063 |
2009 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Arachidonate 12/15-lipoxygenase (12/15-LOX) has been implicated in the pathogenesis of atherosclerosis, but with contradicting results.
|
20676957 |
2010 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The leukocyte-type 12/15-lipoxygenase (12/15-LO) has been implicated in the pathogenesis of atherosclerosis, hypertension, and diabetes.
|
15576842 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Examination of knockout and transgenic animals revealed important roles for 12/15-LOX in inflammatory diseases, including atherosclerosis, cancer, osteoporosis, angiotension II-dependent hypertension and diabetes.
|
16678271 |
2006 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reticulocyte-type 15-lipoxygenase-1 (ALOX15) has anti-inflammatory and inflammatory effects and is implicated in the development of asthma, arthritis and atherosclerosis.
|
17439326 |
2007 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined the role of three single nucleotide polymorphisms (SNPs) in the 15-lipoxygenase gene (ALOX15), in atherosclerosis.
|
18392641 |
2008 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Murine genetic models suggest that function of the 12/15-LOX enzyme promotes atherosclerosis.
|
17959182 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A convincing body of evidence suggests that 12/15-lipoxygenase (12/15-LO) plays a role in atherosclerosis.
|
23589307 |
2013 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
15-Lipoxygenase type 1 (15-LO), a lipid-peroxidating enzyme implicated in physiological membrane remodeling and the pathogenesis of atherosclerosis, inflammation, and carcinogenesis, is highly regulated and expressed in a tissue- and cell-type-specific fashion.
|
15194425 |
2004 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
From these cell culture and animal studies the role of the 15-LOX in human atherosclerosis cannot be predicted.
|
17869078 |
2007 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hyperlipidemia not only affected the biosynthesis of lipoxin A4, a key pro-resolving mediator, but also disrupted the protective pro-resolving function of 12/15-LOX products, and the enzyme pathway no longer protected against atherosclerosis in vivo.
|
21474962 |
2011 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Results from these indicate that 12/15-lipoxygenase expression protects mice against atherosclerosis via its role in the local biosynthesis of lipid mediators, including lipoxin A(4), resolvin D1, and protectin D1.
|
18559988 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genetic or pharmacological inhibition of 12/15-LOX dramatically attenuated the deposition of oxidized LDL in the subendothelial space and the development of atherosclerosis.
|
30300788 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of 15-LOX has been demonstrated in atherosclerosis as well as other inflammatory diseases.
|
30937959 |
2019 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CD-14, MMP-3, ABCA1, Toll-like receptor-4 (TLR-4), lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), arachidonate lipoxygenase-15 (ALOX-15), and Connexin37 polymorphisms and macrophage dysfunction signify their importance in atherosclerosis.
|
18000963 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A great number of studies reported that 12/15-lipoxygenase (12/15-LO) played an important role in atherosclerosis.
|
28701173 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Arachidonate 12/15-lipoxygenase (12/15-LOX) is a member of the lipid peroxidizing enzyme family and plays a major role in atherosclerosis.
|
22351111 |
2012 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Characterization of a human 12/15-lipoxygenase promoter variant associated with atherosclerosis identifies vimentin as a promoter binding protein.
|
22879973 |
2012 |
|
Hypertensive disease
|
0.320 |
Biomarker
|
group |
BEFREE |
The leukocyte- type 12/15-Lipoxygenase (12/15-LO) enzyme and its oxidized lipid products play important roles in vascular smooth muscle cell (VSMC) growth, migration, and matrix responses associated with hypertension, atherosclerosis, and restenosis.
|
15081318 |
2004 |
|
Hypertensive disease
|
0.320 |
Biomarker
|
group |
BEFREE |
12/15-Lipoxygenase (12/15-LO) and its enzymatic products 12(S)- and 15(S)-hydroxyeicosatetraenoic acid (HETE) are essential in the process since disruption of the gene encoding 12/15-LO renders the mice unsusceptible to hypertension.
|
29472381 |
2018 |
|
Esophageal Neoplasms
|
0.310 |
AlteredExpression
|
group |
BEFREE |
These findings demonstrate that 15-LOX-1 is down-regulated in human esophageal carcinomas and that NSAIDs induce apoptosis in esophageal cancer cells via up-regulation of 15-LOX-1.
|
11406566 |
2001 |